The Evidence for Cannabis as an Epilepsy Treatment
About 30% of epilepsy patients don't respond to standard medications—and the clinical evidence for CBD and THC as anticonvulsants has been growing, though regulatory barriers persist.
Quick Facts
What This Study Found
This review summarizes the state of evidence for cannabis-based treatments in epilepsy, focusing on the two main phytocannabinoids: cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC).
The clinical need is real: roughly 30% of epilepsy patients have seizures that resist available medications. CBD has the strongest evidence base, anchored by the FDA-approved Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome. THC also has demonstrated anticonvulsant properties, though its psychoactive effects complicate its clinical use.
The review traces the evidence from early animal studies through to modern clinical trials, documenting how the understanding of cannabis for epilepsy has evolved over the past few decades. The authors note that despite growing evidence, many clinicians and regulatory bodies remain reluctant to prescribe or approve cannabis-based medicines for epilepsy patients.
The gap between evidence and access is a central theme. Patients who might benefit from cannabis medicines often can't get them through standard medical channels, leading some to seek unregulated products—which raises its own safety concerns (see RTHC-00150 on unapproved CBD products in children).
Key Numbers
~30% of epilepsy patients have treatment-resistant seizures. CBD (Epidiolex) is FDA-approved for Dravet syndrome and Lennox-Gastaut syndrome. Both CBD and THC have demonstrated anticonvulsant properties in clinical studies.
How They Did This
Narrative review of the clinical evidence for cannabidiol and THC in epilepsy, covering preclinical studies, clinical trials, and regulatory context.
Why This Research Matters
For the 30% of epilepsy patients with treatment-resistant seizures, the stakes are high—uncontrolled seizures carry risks of injury, cognitive decline, and sudden death. Cannabis-based medicines represent one of the few genuinely novel approaches in a field where most drugs work through similar mechanisms. Understanding the evidence base helps patients and clinicians make informed decisions.
The Bigger Picture
This review provides clinical context for the preclinical work in RTHC-00160 (carvone-derived CBD analogues showing enhanced anti-seizure effects in mice). Together, they illustrate the two tracks of cannabinoid epilepsy research: refining the clinical use of existing plant-derived cannabinoids and developing next-generation synthetic variants. The access barrier issue also connects to broader medical cannabis policy discussions (RTHC-00161 on medical marijuana laws and prescribing patterns).
What This Study Doesn't Tell Us
Narrative reviews reflect the authors' selection of evidence and may not be comprehensive. The review appears to take an advocacy-oriented perspective (calling for more access), which may influence how the evidence is presented. Some of the clinical evidence is from open-label trials without placebo controls.
Questions This Raises
- ?Would wider access to pharmaceutical-grade CBD reduce patients' reliance on unregulated products?
- ?Are there epilepsy subtypes beyond Dravet and Lennox-Gastaut that would benefit from CBD?
- ?What role, if any, should THC play in epilepsy treatment given its psychoactive effects?
Trust & Context
- Key Stat:
- Evidence Grade:
- Narrative review summarizing a range of clinical evidence from animal studies to RCTs—useful for overview but limited by the authors' evidence selection.
- Study Age:
- Published in 2025 with current regulatory and clinical context.
- Original Title:
- Medical Cannabis and Epilepsy: The Evidence.
- Published In:
- British journal of hospital medicine (London, England : 2005), 86(11), 1-20 (2025) — The British Journal of Hospital Medicine is a reputable publication focused on clinical practice and hospital medicine.
- Authors:
- Kaur, Varinder(2), Deacon, Hannah, Barnes, Michael Philip(2), Nutt, David John
- Database ID:
- RTHC-06804
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06804APA
Kaur, Varinder; Deacon, Hannah; Barnes, Michael Philip; Nutt, David John. (2025). Medical Cannabis and Epilepsy: The Evidence.. British journal of hospital medicine (London, England : 2005), 86(11), 1-20. https://doi.org/10.12968/hmed.2024.0903
MLA
Kaur, Varinder, et al. "Medical Cannabis and Epilepsy: The Evidence.." British journal of hospital medicine (London, 2025. https://doi.org/10.12968/hmed.2024.0903
RethinkTHC
RethinkTHC Research Database. "Medical Cannabis and Epilepsy: The Evidence." RTHC-06804. Retrieved from https://rethinkthc.com/research/kaur-2025-medical-cannabis-and-epilepsy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.